Table 2.
Vehicle | Keta (50 mg/kg) | Keta + Olz (5 mg/kg) | Keta + Placebo (50 mg/kg) | Keta + Doxy (25 mg/kg) | Keta + Doxy (50 mg/kg) | Keta + DCNPopt (25 mg/kg) | |
---|---|---|---|---|---|---|---|
Locomotor counts | 283.33 ± 9.61 | 502.66 ± 7.46* | 359.33 ± 10.44a | 490.50 ± 11.55 | 444.83 ± 19.61 | 394.16 ± 8.42a | 304.33 ± 23.4a,x,q |
Stereotyped behaviors | 2.50 ± 0.34 | 27.66 ± 1.14* | 7.83 ± 0.6a | 26.50 ± 0.84 | 21.16 ± 1.74b | 18.66 ± 1.47a | 11.16 ± 1.49a,x,q |
Immobility duration (s) | 72.5 ± 1.61 | 149.83 ± 1.88* | 81.83 ± 1.49a | 146.33 ± 1.99 | 125.16 ± 2.93a | 114.50 ± 3.08a | 81.16 ± 5.16a,x,p |
SDL (s) | 237.66 ± 14.55 | 76.83 ± 3.98* | 186 ± 2.22a | 74.16 ± 4.01 | 80.16 ± 4.52 | 80.50 ± 4.52 | 90.83 ± 3.17# |
TNF-α (ng/ml) | 125.16 ± 3.65 | 499.66 ± 9.62* | 128.00 ± 2.58a | 495.33 ± 12.02 | 378.66 ± 5.56a | 330.33 ± 15.51a | 147.33 ± 4.77a,x,p |
GSH (nmol/mg protein) | 0.0051 ± 0.00020 | 0.0015 ± 0.00011* | 0.0051 ± 0.00016a | 0.0016 ± 9.38E-50 | 0.0029 ± 2.72E-04a | 0.0038 ± 0.00011a | 0.0053 ± 1.69E-03a,x,p |
MDA (nmol/mg protein) | 0.252 ± 0.014 | 0.563 ± 0.019* | 0.228 ± 0.011a | 0.558 ± 0.020 | 0.424 ± 0.010a | 0.396 ± 0.007a | 0.208 ± 0.08a,x,p |
AchE (nmol/min/g protein) | 38.82 ± 1.24 | 65.24 ± 2.05* | 36.68 ± 1.92a | 64.79 ± 3.90 | 64.74 ± 1.68 | 64.25 ± 3.11 | 62.67 ± 1.41# |
Dopamine (pg/mg brain) | 427.38 ± 27.11 | 981.73 ± 30.68* | 429.62 ± 29.03a | 978.40 ± 25.40 | 688.33 ± 21.12a | 642.93 ± 27.21a | 435.16 ± 21.55a,x,p |
GABA (μg/g brain) | 192.58 ± 6.75 | 107.80 ± 6.06* | 208.88 ± 8.80a | 106.42 ± 6.11 | 147.50 ± 3.22a | 155.99 ± 3.56a | 211.30 ± 5.62a,x,p |
Values are expressed as mean ± SEM (n = 6).
p < .001 vs vehicle group.
p < .001 vs ketamine group.
p < .001 vs Keta + Doxy (25 mg/kg).
p < .001 vs Keta + Doxy (50 mg/kg).
p < .01 vs Keta + Doxy (50 mg/kg).
p < .001 vs olanzapine.
Keta: Ketamine; Olz: Olanzapine; Doxy: Doxycycline hydrochloride; DCNPopt: Optimized Doxycycline hydrochloride Chitosan Nanoparticles.